| Date Filed | Type | Description |
| 10/12/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/10/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 250 shares
@ $11.27, valued at
$2.8k
Bought 830 shares
@ $11.19, valued at
$9.3k
|
|
| 10/06/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 1,820 shares
@ $10.95, valued at
$19.9k
Bought 1,400 shares
@ $11.09, valued at
$15.5k
|
|
| 08/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma August 17, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that NXP800 was granted Orphan Drug Designation by the United States Food and Drug Administration for the treatment of cholangiocarcinoma. Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, commented, "We are pleased to have received this designation from the FDA for NXP800, which emphasizes the need for new, innovative therapies for the treatment of cholangiocarcinoma, a deadly malignancy with only limited treatme..." |
|
| 08/16/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 235 shares
@ $14.34, valued at
$3.4k
Bought 115 shares
@ $15.15, valued at
$1.7k
|
|
| 08/11/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 120 shares
@ $14.83, valued at
$1.8k
Bought 180 shares
@ $14.66, valued at
$2.6k
|
|
| 08/09/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/31/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/28/2023 |
4
| Mosseri Marlio Charles (10% Owner) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 1,556 shares
@ $13.98, valued at
$21.8k
|
|
| 07/27/2023 |
4
| Mosseri Marlio Charles (10% Owner) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 10,000 shares
@ $13.97, valued at
$139.7k
|
|
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/18/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 110 shares
@ $16.19, valued at
$1.8k
Bought 150 shares
@ $15.03, valued at
$2.3k
|
|
| 07/13/2023 |
4
| Mosseri Marlio Charles (10% Owner) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 3,285 shares
@ $15.09, valued at
$49.6k
|
|
| 07/12/2023 |
4
| Mosseri Marlio Charles (10% Owner) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 10,000 shares
@ $15.36, valued at
$153.6k
|
|
| 07/10/2023 |
4
| Mosseri Marlio Charles (10% Owner) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 8,948 shares
@ $15.19, valued at
$135.9k
|
|
| 07/07/2023 |
4
| Mosseri Marlio Charles (10% Owner) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 3,179 shares
@ $15.01, valued at
$47.7k
|
|
| 07/07/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 320 shares
@ $14.88, valued at
$4.8k
|
|
| 07/06/2023 |
4
| Mosseri Marlio Charles (10% Owner) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 1,176 shares
@ $15.52, valued at
$18.3k
|
|
| 07/03/2023 |
8-K
| Results of Operations and Financial Condition Interactive Data |
| 06/16/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/16/2023 |
4
| Mosseri Marlio Charles (10% Owner) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 400 shares
@ $17.54, valued at
$7k
Bought 31,724 shares
@ $17.71, valued at
$561.8k
|
|
| 06/08/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 230 shares
@ $17.41, valued at
$4k
Bought 120 shares
@ $17.53, valued at
$2.1k
|
|
| 06/01/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 330 shares
@ $17.28, valued at
$5.7k
|
|
| 05/26/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 200 shares
@ $17.49, valued at
$3.5k
|
|
| 05/18/2023 |
4
| BENTSUR RON (Chairman & CEO) has filed a Form 4 on Nuvectis Pharma, Inc.|
Txns:
| Bought 320 shares
@ $17.025, valued at
$5.4k
|
|
| 05/15/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Nuvectis Pharma Announces FDA Clearance of NXP900 IND May 15, 2023, Fort Lee, NJ - Nuvectis Pharma, Inc. , a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that the U.S. Food and Drug Administration cleared the Company's Investigational New Drug Application for NXP900, which includes the Phase 1 clinical trial protocol. “The IND clearance by the FDA is a significant milestone for the NXP900 development program and for our overall corporate strategy, further demonstrating our ability to execute our business plan,” said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. Mr. Bentsur continued, “Nuvectis now has two precision oncology, cl..." |
|
| 05/10/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
|